Identificação da Expressão das Variantes 1 e 2 do Gene que Codifica a Fosfatase Alcalina em Células Tronco Derivadas de Tecido Adiposo Induzidas com Dexametasona

Abstract

Stem cells are undifferentiated and pluripotent cells that are able to differentiate into several cell types. Stem cells are distinguished from other cell types by two important characteristics: self-renewal and differentiation potential. Due to their differentiation potential and easiness for isolate and growth in vitro, mesenchymal stem cells (MSCs) are widely used in trials for the treatment of numerous diseases such as heart disease, myeloma and osteoarthritis. The corticosteroid dexamethasone is broadly used to induce bone differentiation in stem cells and is involved in the increased activity of alkaline phosphatase (ALPL). There are four genes coding ALP: ALPL, ALPP, ALPPL2 and ALPI. The ALPL is one of the main markers for bone differentiation stimulated by dexamethasone. This gene has three different variants which are generated by alternative splicing. However, to date it is not known which of these variants act in the bone matrix deposition. In this context, the aim of this work was to analyze the activity of ALPL variants during the differentiation of MSCs treated with dexamethasone. Primers for the three ALPL variants were designed by our group. For the experiment, approximately 3x10 4 cells per ml were seeded in culture plate. For treatment, we used 10 -7 M dexamethasone for 0, 3 and 7 days. The qPCR results showed that the primers designed had an amplification efficiency higher than 90% and R 2 = 1; variant 2 (V2) primers was more efficient than the variant 1 (V1) primers and primers of both variants are more efficient than the currently used ALP primers. The primers of ALPL/v3 showed no amplification. Our statistical data showed that the differences in expression between treated and control cells were significant, indicating an expressive increase of ALPL/v1 in treated cells. The expression of ALPL/v2, although significant between controls and treated cells, was low when compared to ALPL/v1. The results of this study indicate that dexamethasone, besides increasing the activity of the ALPL promoter, gives preference to alternative splicing that originates the variant1 mRNA.